enGene (ENGN) to Release Earnings on Thursday

enGene (NASDAQ:ENGN) will likely be releasing its Q4 2025 results before the market opens on Thursday, December 18th. Analysts expect the company to announce earnings of ($0.55) per share for the quarter. Parties are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Friday, December 26, 2025 at 4:00 PM ET.

enGene Trading Down 0.6%

enGene stock opened at $8.38 on Wednesday. enGene has a 52 week low of $2.65 and a 52 week high of $11.14. The stock has a market cap of $541.18 million, a PE ratio of -4.41 and a beta of -0.28. The stock has a 50-day moving average price of $7.89 and a 200 day moving average price of $5.67. The company has a current ratio of 10.34, a quick ratio of 10.34 and a debt-to-equity ratio of 0.09.

Analysts Set New Price Targets

ENGN has been the subject of several analyst reports. Oppenheimer reiterated an “outperform” rating and issued a $33.00 price target (up from $30.00) on shares of enGene in a report on Wednesday, November 12th. UBS Group upped their price target on enGene from $4.00 to $10.00 and gave the stock a “neutral” rating in a research note on Wednesday, November 12th. Weiss Ratings restated a “sell (d-)” rating on shares of enGene in a report on Tuesday, October 14th. Raymond James Financial raised shares of enGene from an “outperform” rating to a “strong-buy” rating and set a $27.00 price target for the company in a research report on Tuesday, November 11th. Finally, Citizens Jmp raised their price objective on enGene from $18.00 to $21.00 and gave the company a “market outperform” rating in a research report on Wednesday, November 12th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $22.38.

Institutional Trading of enGene

Several institutional investors have recently added to or reduced their stakes in ENGN. Millennium Management LLC increased its holdings in enGene by 57.3% in the third quarter. Millennium Management LLC now owns 20,502 shares of the company’s stock valued at $140,000 after buying an additional 7,472 shares during the last quarter. Citadel Advisors LLC increased its stake in enGene by 153.3% during the third quarter. Citadel Advisors LLC now owns 58,370 shares of the company’s stock valued at $399,000 after purchasing an additional 35,327 shares during the last quarter. Raymond James Financial Inc. raised its holdings in shares of enGene by 383.6% during the third quarter. Raymond James Financial Inc. now owns 10,000 shares of the company’s stock worth $68,000 after purchasing an additional 7,932 shares during the period. Paloma Partners Management Co bought a new position in shares of enGene in the 2nd quarter worth about $38,000. Finally, Cresset Asset Management LLC bought a new stake in shares of enGene during the 2nd quarter valued at about $36,000. 64.16% of the stock is owned by institutional investors and hedge funds.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.